Discovery of an MLLT1/3 YEATS Domain Chemical Probe

YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine‐binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small‐molecule chemic...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2018-12, Vol.57 (50), p.16302-16307
Main Authors: Moustakim, Moses, Christott, Thomas, Monteiro, Octovia P., Bennett, James, Giroud, Charline, Ward, Jennifer, Rogers, Catherine M., Smith, Paul, Panagakou, Ioanna, Díaz‐Sáez, Laura, Felce, Suet Ling, Gamble, Vicki, Gileadi, Carina, Halidi, Nadia, Heidenreich, David, Chaikuad, Apirat, Knapp, Stefan, Huber, Kilian V. M., Farnie, Gillian, Heer, Jag, Manevski, Nenad, Poda, Gennady, Al‐awar, Rima, Dixon, Darren J., Brennan, Paul E., Fedorov, Oleg
Format: Article
Language:English
Subjects:
chemical probes
Communication
Communications
Crystal structure
Crystallography, X-Ray
Drug discovery
epigenetics
Histones - metabolism
Humans
Lysine
MLLT1
MLLT3
Molecular Docking Simulation
Neoplasm Proteins - antagonists & inhibitors
Neoplasm Proteins - chemistry
Neoplasm Proteins - metabolism
Nuclear Proteins - antagonists & inhibitors
Nuclear Proteins - chemistry
Nuclear Proteins - metabolism
Organic chemistry
Protein Domains
Protein Interaction Maps - drug effects
Proteins
Selectivity
Small Molecule Libraries - chemistry
Small Molecule Libraries - pharmacology
Transcription Factors - antagonists & inhibitors
Transcription Factors - chemistry
Transcription Factors - metabolism
YEATS
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine‐binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small‐molecule chemical probe, SGC‐iMLLT, for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). SGC‐iMLLT is a potent and selective inhibitor of MLLT1/3–histone interactions. Excellent selectivity over other human YD proteins (YEATS2/4) and bromodomains was observed. Furthermore, our probe displays cellular target engagement of MLLT1 and MLLT3. The first small‐molecule X‐ray co‐crystal structures with the MLLT1 YD are also reported. This first‐in‐class probe molecule can be used to understand MLLT1/3‐associated biology and the therapeutic potential of small‐molecule YD inhibitors. Molecular poetry: YEATS domain (YD) containing proteins are an emerging class of epigenetic protein targets in drug discovery. A screening hit has been developed into the first potent, selective, and cell‐active chemical probe for the YD‐containing proteins MLLT1 and MLLT3. The probe represents the first inhibitor of its class to explore YD‐associated biology and disease links.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.201810617